U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H15ClFN5O5S2
Molecular Weight 523.945
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELINOGREL

SMILES

CNC1=CC2=C(C=C1F)C(=O)N(C(=O)N2)C3=CC=C(NC(=O)NS(=O)(=O)C4=CC=C(Cl)S4)C=C3

InChI

InChIKey=LGSDFTPAICUONK-UHFFFAOYSA-N
InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)

HIDE SMILES / InChI

Molecular Formula C20H15ClFN5O5S2
Molecular Weight 523.945
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800022611 | http://www.wikidoc.org/index.php/Elinogrel

Elinogrel, previously known as PRT060128 or PRT128, is a direct-acting, reversible P2Y12 inhibitor for both intravenous and oral administration. Elinogrel has been tested in 2 phase II studies for the treatment of acute coronary syndrome, myocardial infarction and prevention of secondary thrombotic events. Elinogrel therapy was associated with an increased incidence of dyspnea and incidence of elevated liver transaminases. The development of the drug was terminated in January 2012 by Novartis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
23.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
150 mg 2 times / day multiple, oral (max)
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.339, 340
unhealthy, ADULT
n = 408
Health Status: unhealthy
Condition: coronary artery disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 408
Sources: Page: p.339, 340
Disc. AE: Dyspnea...
AEs leading to
discontinuation/dose reduction:
Dyspnea (grade 1-2, 1%)
Sources: Page: p.339, 340
AEs

AEs

AESignificanceDosePopulation
Dyspnea grade 1-2, 1%
Disc. AE
150 mg 2 times / day multiple, oral (max)
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.339, 340
unhealthy, ADULT
n = 408
Health Status: unhealthy
Condition: coronary artery disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 408
Sources: Page: p.339, 340
PubMed

PubMed

TitleDatePubMed
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.
2009 Apr
New P2Y12 antagonists.
2009 Sep
Emerging antiplatelet agents, differential pharmacology, and clinical utility.
2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
2010 Apr
Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.
2010 Jun 1
Newer antithrombotic drugs.
2010 Oct
Patents

Sample Use Guides

80-mg intravenous bolus of elinogrel was given immediately before percutaneous coronary intervention, followed by twice-daily oral elinogrel administration of 50, 100, or 150 mg for 60 days
Route of Administration: Other
When two concentrations of elinogrel (2.5 or 5.0 mmol/l) were added in vitro to the blood of diabetic patients, an anti-thrombotic effect was observed, supporting evidence that elinogrel may overcome the limitation of poor clopidogrel response.
Substance Class Chemical
Created
by admin
on Thu Jul 06 22:09:58 UTC 2023
Edited
by admin
on Thu Jul 06 22:09:58 UTC 2023
Record UNII
915Y8E749J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELINOGREL
INN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
Elinogrel [WHO-DD]
Common Name English
ELINOGREL [MI]
Common Name English
PRT 060128
Code English
elinogrel [INN]
Common Name English
5-CHLORO-N-((4-(6-FLUORO-7-(METHYLAMINO)-2,4-DIOXO-1,4-DIHYDROQUINAZOLIN-3(2H)-YL)PHENYL)CARBAMOYL)THIOPHENE-2-SULFONAMIDE
Systematic Name English
ELINOGREL [USAN]
Common Name English
PRT-060128
Code English
2-THIOPHENESULFONAMIDE, 5-CHLORO-N-(((4-(6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL)PHENYL)AMINO)CARBONYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C80483
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
Code System Code Type Description
MESH
C549473
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
PUBCHEM
16066663
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
ChEMBL
CHEMBL2103828
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
NCI_THESAURUS
C96896
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
USAN
UU-95
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
INN
9154
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
EVMPD
SUB120965
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
FDA UNII
915Y8E749J
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
MERCK INDEX
M4870
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
Elinogrel
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
SMS_ID
100000144446
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
CAS
936500-94-6
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
DRUG BANK
DB06350
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
EPA CompTox
DTXSID50918262
Created by admin on Thu Jul 06 22:09:59 UTC 2023 , Edited by admin on Thu Jul 06 22:09:59 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY